The Mitochondria‐Targeted Peptide Therapeutic Elamipretide Improves Cardiac and Skeletal Muscle Function During Aging Without Detectable Changes in Tissue Epigenetic or Transcriptomic Age

Abstract excerpt

Aging-related decreases in cardiac and skeletal muscle function are strongly associated with various comorbidities. Elamipretide (ELAM), a novel mitochondria-targeted peptide, has demonstrated broad therapeutic efficacy in ameliorating disease conditions associated with mitochondrial dysfunction across both clinical and pre-clinical models. Herein, we investigated the impact of 8-week ELAM treatment on pre- and...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to GDF15 and Related Biomarkers
• Share to Genetics and Neurodevelopmental Disorders
• Share to Mitochondrial Function and Pathology